Phreesia (PHR) Aandelenoverzicht
Phreesia, Inc. levert een geïntegreerd SaaS-gebaseerd software- en betalingsplatform voor de gezondheidszorg in de Verenigde Staten en Canada. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
PHR Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Phreesia, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$12.00 |
| 52 Week Hoogtepunt | US$32.76 |
| 52 Week Laag | US$7.77 |
| Bèta | 0.84 |
| 1 maand verandering | 13.21% |
| 3 maanden verandering | 34.53% |
| 1 Jaar Verandering | -58.28% |
| 3 jaar verandering | -54.53% |
| 5 jaar verandering | -82.39% |
| Verandering sinds IPO | -52.15% |
Recent nieuws en updates
Narratiefupdate • Jul 16
PHR: Securities Lawsuit And Weak Growth Visibility Will Pressure Shares
The analyst price target for Phreesia has been revised from $24 to $9, as analysts weigh lower modeled revenue growth, a reduced assumed future P/E multiple, and sector research that highlights competitive pressures, softer digital advertising trends, and limited visibility into a return to durable organic growth. Analyst Commentary on Phreesia Recent research on Phreesia points to a more cautious stance from several bearish analysts, with multiple downgrades and lower price targets reflecting concerns about growth visibility, competition, and the balance between profitability efforts and future expansion.
Narratiefupdate • Jul 01
PHR: Cost Discipline And Profit Focus Will Drive Long Term Upside
Phreesia's analyst fair value estimate has been reduced from $35.00 to $20.00, reflecting lower assumed revenue growth and profit margins as analysts weigh slower digital advertising trends, rising competitive pressure, and less visibility into a return to durable organic growth. Analyst Commentary Recent Street research on Phreesia highlights a more cautious tone, with several firms cutting ratings and trimming price targets as they reassess growth visibility, digital advertising trends, and competitive pressure.
Narratiefupdate • Jun 17
PHR: Cost Discipline And Profit Focus Will Support Stock Multiple Recovery
Analysts have trimmed their average price target on Phreesia stock by a few dollars into the low teens. This reflects concern that cost cutting is coming alongside reduced visibility on organic growth and rising competitive pressure in digital health advertising.Recent updates
Narratiefupdate • Jul 16
PHR: Securities Lawsuit And Weak Growth Visibility Will Pressure Shares
The analyst price target for Phreesia has been revised from $24 to $9, as analysts weigh lower modeled revenue growth, a reduced assumed future P/E multiple, and sector research that highlights competitive pressures, softer digital advertising trends, and limited visibility into a return to durable organic growth. Analyst Commentary on Phreesia Recent research on Phreesia points to a more cautious stance from several bearish analysts, with multiple downgrades and lower price targets reflecting concerns about growth visibility, competition, and the balance between profitability efforts and future expansion.Narratiefupdate • Jul 01
PHR: Cost Discipline And Profit Focus Will Drive Long Term Upside
Phreesia's analyst fair value estimate has been reduced from $35.00 to $20.00, reflecting lower assumed revenue growth and profit margins as analysts weigh slower digital advertising trends, rising competitive pressure, and less visibility into a return to durable organic growth. Analyst Commentary Recent Street research on Phreesia highlights a more cautious tone, with several firms cutting ratings and trimming price targets as they reassess growth visibility, digital advertising trends, and competitive pressure.Narratiefupdate • Jun 17
PHR: Cost Discipline And Profit Focus Will Support Stock Multiple Recovery
Analysts have trimmed their average price target on Phreesia stock by a few dollars into the low teens. This reflects concern that cost cutting is coming alongside reduced visibility on organic growth and rising competitive pressure in digital health advertising.Seeking Alpha • Jun 15
Phreesia: Rating Downgrade As Growth Outlook Worsens
Summary Phreesia is downgraded to Hold as profitability improves, but growth outlook becomes less compelling. PHR's EBITDA and free cash flow are rising, but revenue growth is slowing and increasingly reliant on acquired payments. Subscription revenue is declining, and organic payment solutions growth remains weak despite the AccessOne acquisition. Valuation is historically low; upside depends on evidence of organic growth and successful cross-selling of AccessOne. Read the full article on Seeking AlphaAnalyse-artikel • Jun 10
Phreesia's (NYSE:PHR) Performance Is Even Better Than Its Earnings Suggest
Phreesia, Inc.'s ( NYSE:PHR ) strong earnings report was rewarded with a positive stock price move. Our analysis found...Narratiefupdate • Jun 01
PHR: Cost Discipline And Higher Margins Will Support Multiple Recovery
Analysts have reduced their average price target for Phreesia by about $1, to roughly $14. Lower revenue growth expectations and multiple downgrades related to growth visibility and competitive pressures are only partly offset by improving profit margin assumptions and a lower projected P/E.Narratiefupdate • May 17
PHR: Post Reset Execution On Profitability And Intake Reach Will Support Multiple
Analysts have trimmed their fair value estimate for Phreesia from about $16.17 to $15.39 and lowered the future P/E assumption, reflecting a broad reset in price targets as firms point to slowing digital advertising growth and rising competition. Analyst Commentary Recent research points to a sharp reset in expectations for Phreesia, with multiple firms cutting price targets and, in several cases, downgrading ratings.Narratiefupdate • Apr 24
PHR: Post Guidance Reset Execution On Profitability And Intake Reach Will Support Multiple
The updated analyst price target for Phreesia reflects a modest downward adjustment of around $0.28, with analysts pointing to slightly lower assumptions for revenue growth, profit margin, and future P/E, along with a small change in the discount rate. Analyst Commentary Recent research updates on Phreesia have been concentrated on lowering price targets and, in several cases, revising ratings, which points to a clear reset in expectations around growth, profitability, and execution risk.Narratiefupdate • Apr 10
PHR: Profitability Focus And Intake Reach Will Support Post Guidance Reset Multiple Resilience
Analysts have reduced their average price target on Phreesia to reflect a lower fair value estimate of about $16.44, down from roughly $27.89. They cited more conservative assumptions for revenue growth, profit margins and future P/E multiples after a broad wave of target cuts and downgrades from multiple firms.Narratiefupdate • Mar 26
PHR: Profitability Focus And Intake Reach Will Support Future Multiple Resilience
Analyst price targets on Phreesia have been trimmed by a few dollars to around the mid $20s, as analysts factor in slightly lower revenue growth and profit margin assumptions while still using a relatively high future P/E of about 37x. Analyst Commentary Recent Street research on Phreesia has centered on fine tuning price targets and reassessing how much investors should pay for the company’s earnings profile, rather than making wholesale shifts in views on the business itself.Narratiefupdate • Mar 11
PHR: Profitability Pivot And Intake Network Breadth Will Support Future Margin Expansion
Analysts have trimmed their average price targets on Phreesia by roughly $5 to the mid $20s, reflecting a mix of caution after a challenging period for health tech stocks and continued confidence in the company’s profitability pivot and patient intake platform. Analyst Commentary Recent Street research on Phreesia clusters around a common theme, lower price targets but generally constructive views on the company’s execution and path to profitability.Narratiefupdate • Feb 24
PHR: Profitability Pivot And AccessOne Integration Will Drive Future Margin Expansion
The updated analyst price target for Phreesia reflects a modest trim of fair value to about $28.05, as analysts recalibrate their models following a series of target cuts to the $24 to $30 range. They continue to cite the company’s profitability pivot and patient intake platform scale as key parts of the long-term thesis.Narratiefupdate • Feb 10
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts have nudged their price targets on Phreesia slightly lower, trimming fair value estimates by about $0.32 to reflect modestly updated assumptions on discount rates, margins, and future P/E. At the same time, recent research highlights both reduced targets in health tech and continued optimism around the company’s patient intake and payments platform.Narratiefupdate • Jan 26
PHR: Profitability Pivot And AccessOne Synergies Will Support Future EBITDA Improvement
Analysts have nudged their fair value estimate for Phreesia slightly lower to about $28.63 per share, reflecting modestly softer assumptions for revenue growth, profit margins, and future P/E multiples following a series of recent price target cuts and fresh coverage initiations. Analyst Commentary Recent research paints a mixed picture for Phreesia, with several firms trimming price targets while others initiate or resume positive ratings.Narratiefupdate • Jan 12
PHR: Profitability Pivot And AccessOne Integration Will Support Future Margin Expansion
Analysts trimmed their fair value estimate for Phreesia to about $29.16 from $29.82 and lowered future P/E assumptions, pointing to reduced Street price targets in the mid $20s, even as research notes highlight the company’s profitability focus, margin progress, and reach across U.S. patient visits. Analyst Commentary Street research on Phreesia is mixed, with several firms trimming price targets while still highlighting profitability efforts, margin progress, and the scale of the platform across U.S. patient visits.Narratiefupdate • Dec 24
PHR: Cross Sell And AccessOne Integration Will Drive Future EBITDA Expansion
Narrative Update Analysts have modestly trimmed their price target on Phreesia to approximately $29.82 from about $32.12 per share, reflecting slightly lower assumptions for revenue growth and profit margins even as they highlight the company’s growing cross-sell traction, long-term lift from the pending AccessOne acquisition, and potential for significant operating leverage to drive EBITDA growth in the high-20s to low-30s percentage range. Analyst Commentary Analysts generally view Phreesia positively, with recent coverage initiating the stock with an Outperform rating and a price target modestly above current levels, citing a strengthening growth and profitability profile.Narratiefupdate • Dec 10
PHR: Cross Selling Momentum Will Drive Stronger Long Term EBITDA Expansion
Analysts have modestly reduced their price target on Phreesia from $33.73 to $32.12 per share, citing expectations for stronger long term EBITDA growth supported by cross selling traction and operating leverage, as well as incremental upside from the pending AccessOne acquisition. Analyst Commentary Analysts highlight that Phreesia's current valuation reflects confidence in its ability to execute on growth initiatives while expanding margins, but they also caution that the shares already price in a meaningful portion of the long term opportunity.Analyse-artikel • Sep 27
Phreesia, Inc.'s (NYSE:PHR) 26% Cheaper Price Remains In Tune With Revenues
Phreesia, Inc. ( NYSE:PHR ) shareholders won't be pleased to see that the share price has had a very rough month...Narratiefupdate • Sep 06
AI Integration And Digital Adoption Will Expand Healthcare Services
Phreesia’s price target increased to $33.73 as analysts responded positively to solid Q2 results, upwardly revised FY26 EBITDA guidance, strategic product launches, and the AccessOne acquisition—despite valuation concerns—supporting a strong double-digit growth outlook and margin expansion. Analyst Commentary Solid Q2 results, with revenues in line and adjusted EBITDA ahead of consensus; company raised FY26 EBITDA guidance driven by effective expense management.Nieuw narratief • May 27
Digital Healthcare Tools Will Expand Market Reach
Expanding digital adoption and data-driven solutions are driving operational efficiency, deeper client relationships, and long-term recurring revenue growth.Analyse-artikel • Apr 29
Revenues Tell The Story For Phreesia, Inc. (NYSE:PHR)
There wouldn't be many who think Phreesia, Inc.'s ( NYSE:PHR ) price-to-sales (or "P/S") ratio of 3.4x is worth a...Analyse-artikel • Mar 07
Why Phreesia, Inc. (NYSE:PHR) Could Be Worth Watching
Phreesia, Inc. ( NYSE:PHR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Analyse-artikel • Feb 14
Phreesia (NYSE:PHR) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyse-artikel • Dec 27
Phreesia, Inc.'s (NYSE:PHR) Shares Climb 27% But Its Business Is Yet to Catch Up
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Dec 12
Phreesia Has Turned The Corner, Can It Continue To Mend?
Summary Phreesia’s Q3 earnings show solid revenue growth, but customer growth is decelerating, impacting overall performance. Fiscal 2025 guidance improved with higher EBITDA and tighter revenue estimates, while fiscal 2026 projects slower revenue growth but significant EBITDA improvement. Strong cash flow and disciplined expense management are encouraging, with the company maintaining positive cash flows and holding $82M in cash. Despite current trading challenges, Phreesia’s innovative healthcare solutions and partnerships position it well for future growth and potential valuation recovery. Read the full article on Seeking AlphaAnalyse-artikel • Nov 07
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues
With a price-to-sales (or "P/S") ratio of 3.1x Phreesia, Inc. ( NYSE:PHR ) may be sending bearish signals at the...Analyse-artikel • Oct 08
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyse-artikel • Sep 06
Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results
Phreesia, Inc. ( NYSE:PHR ) last week reported its latest second-quarter results, which makes it a good time for...Seeking Alpha • Sep 05
Phreesia: Remain Bullish Given The Healthy Growth Outlook
Summary I maintain a buy rating for PHR, driven by strong client growth, solid revenue outlook, and increasing transaction sizes in the pipeline. PHR's 2Q25 results show 19% y/y revenue growth and improved profitability, with positive EBITDA and FCF, indicating strong financial health. Despite a slight decline in revenue per AHSC, larger client acquisitions and increased transaction sizes support my 20% growth expectation. Read the full article on Seeking AlphaAnalyse-artikel • Jul 18
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher
Phreesia, Inc. ( NYSE:PHR ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jun 06
Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve
Summary Phreesia's revenue grew 20.7% year-over-year, with subscription revenue growing 23.4% and payment processing revenue growing 11.6%. The company added 103 new clients in the quarter, beating guidance, and expects to add around 100 more in the next quarter. Phreesia's focus on profitability is showing positive results, with EBITDA margin expanding and guidance suggesting further improvement. Read the full article on Seeking AlphaRendement voor aandeelhouders
| PHR | US Healthcare Services | US Markt | |
|---|---|---|---|
| 7D | -4.9% | 5.1% | -0.8% |
| 1Y | -58.3% | -19.4% | 20.5% |
Rendement versus industrie: PHR presteerde slechter dan de US Healthcare Services -sector, die het afgelopen jaar een rendement van -19.4 % opleverde.
Rendement versus markt: PHR presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 20.5 % opleverde.
Prijsvolatiliteit
| PHR volatility | |
|---|---|
| PHR Average Weekly Movement | 7.5% |
| Healthcare Services Industry Average Movement | 10.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: PHR heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van PHR is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2005 | 1,789 | Chaim Indig | www.phreesia.com |
Phreesia, Inc. biedt een geïntegreerd SaaS-gebaseerd software- en betalingsplatform voor de gezondheidszorg in de Verenigde Staten en Canada. Het biedt oplossingen voor het optimaliseren van afspraken en het beheer van verwijzingen met behulp van AI-gebaseerde workflows; en AI-gebaseerde intelligente antwoordoplossingen voor patiëntencommunicatie ondersteund door spraak- en berichtoplossingen; geïntegreerde betalingsoplossingen die zijn ingebed in intake- en post-bezoekworkflows, en financieringsoplossingen die zorgorganisaties in staat stellen om sneller geld in te zamelen en tegelijkertijd flexibele betalingsopties aan te bieden aan patiënten; en digitale intake en klinische gegevensvastlegging, tools voor patiëntenbetrokkenheid en -activering, en meet- en analyseoplossingen. Het bedrijf biedt ook PhreesiaPads, zelfbedieningsintaketabletten, en Arrivals Kiosks, kiosken op locatie.
Phreesia, Inc. Samenvatting
| PHR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$739.27m |
| Inkomsten(TTM) | US$9.18m |
| Inkomsten(TTM) | US$495.59m |
80.8x
Koers/Winstverhouding1.5x
P/S-verhoudingIs PHR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| PHR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$495.59m |
| Kosten van inkomsten | US$159.39m |
| Brutowinst | US$336.20m |
| Overige uitgaven | US$327.02m |
| Inkomsten | US$9.18m |
Laatst gerapporteerde inkomsten
Apr 30, 2026
Volgende inkomensdatum
Sep 02, 2026
| Winst per aandeel (EPS) | 0.15 |
| Brutomarge | 67.84% |
| Nettowinstmarge | 1.85% |
| Schuld/Eigen Vermogen Verhouding | 23.6% |
Hoe presteerde PHR op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/20 02:28 |
| Aandelenkoers aan het einde van de dag | 2026/08/20 00:00 |
| Inkomsten | 2026/04/30 |
| Jaarlijkse inkomsten | 2026/01/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Phreesia, Inc. wordt gevolgd door 23 analisten. 18 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Joseph Vruwink | Baird |
| Glen Santangelo | Barclays |
| Zhilin Long | Berenberg |